Article -> Article Details
| Title | Why Are Pharmaceutical and Biopharmaceutical Companies Using Laboratory Filtration Products? |
|---|---|
| Category | Business --> Business Services |
| Meta Keywords | Laboratory Filtration Market |
| Owner | industrytrends |
| Description | |
| The World Health Organization (WHO) estimates that approximately 41 million people each year die due to non-communicable diseases (NCDs), accounting for around 71% of global deaths. The WHO also states that nearly 17.9 million, 9.3 million, 4.1 million, and 1.5 million human lives are lost due to cardiovascular diseases (CVDs), cancer, respiratory diseases, and diabetes, respectively, each year. Due to the rising cases of NCDs, pharmaceutical companies are increasingly focusing on introducing new medicines and engaging in clinical trials to reduce the mortality rate and minimize the consequences on the human body. Apart from the pharmaceutical industry, the food and beverage sector also uses a substantial volume of laboratory filtration products, owing to the exceptional results obtained by the purification, concentration, fractionation, and clarification processes that are carried out with the help of membrane filtration. Thus, the escalating demand for good quality food items and beverages, owing to the mounting health awareness will create a huge requirement for filtration products, such as filtration media, filtration assemblies, and filtration accessories, and filtration technology like microfiltration, ultrafiltration, reverse osmosis, nanofiltration, and vacuum filtration. In recent years, laboratory filtration product and technology providers, such as General Electric Company, Sartorius AG, Cantel Medical Corporation, MACHEREY-NAGEL GmbH & Co. KG, 3M Company, Thermo Fisher Scientific Inc., and Danaher Corporation, have focused on developing and introducing new and innovative products to cater to a greater number of customers. For example, in 2017, Merck KGaA introduced Milli-Q IQ 7000 system, which offers ech2o mercury-free UV lamps for the photooxidation of organic contaminants and provides purification cartridges that are 33% smaller than its previous versions. Likewise, in September 2017, Merck KGaA introduced Millistak+ HC Pro, which is a more consistent and cleaner depth filtration process than conventional diatomaceous earth and cellulose-based filtration processes. This product is a high-capacity and fully synthetic depth filter media designed for harvest clarification and downstream filtration of the non-treated Chinese hamster ovary. In the same vein, the company launched Viresolve barrier capsule filters in February 2018. These filters can remove bacteria, viruses, and mycoplasma from cell culture media. Increasing number of research activities in pharmaceutical and biopharmaceutical industries and growing usage of filtration products are also boosting the growth of the laboratory filtration market. Besides, clinical research in pharmaceutical companies and scientific institutions (such as university clinics) is resulting in the development of new and tried-and-tested medicines or active ingredients, which, in turn, is contributing to the market growth. According to P&S Intelligence, the Asia-Pacific (APAC) laboratory filtration market will progress at the highest rate in the forthcoming future, owing to the improving healthcare infrastructure, surging production of pharmaceutical products, and rising incidence of chronic illnesses in the region. For instance, the International Diabetes Federation (IDF) states that 1,010,262,100 diabetes-related deaths were recorded in India among people within the age group of 20–79 years in 2019. The IDF also forecasts that nearly 11.5% of the Indian population within this age bracket will be living with diabetes by 2045. Thus, the increasing incidence of chronic ailments and the rising health awareness will fuel the adoption of laboratory filtration products globally. | |